$XBI $123.91 +1.32
Covid Updates
$VXRT -0.14% New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model. source
Pipeline Updates
$MRTX +3.4% Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer. source
$ALLO +1.7% Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial. source
$ELOX +1.3% Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs. source
$MRSN +0.8% Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. source
$AERI +3.2% Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase. source
$NKTX +4.6% Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs. source
$BCYC +16.8% Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial. source
$LVTX +1.3% LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. source
$RAIN -8.2% Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. source
$JAGX +4.1% Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.. source
$IMV -0.9% Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. source
$SPPI +2.6% Spectrum Pharmaceuticals Announces Presentation of Poziotinib in Combination with KRASG12C Inhibitors at the 2021 AACR-NCI-EORTC Conference. source
$PRLD -39.8% Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. source
$IKNA +9.2% Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment. source
$KNTE +0.3% Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference. source
$CLVS +1.9% Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286. source
$YMAB -0.5% Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA. source
$ORIC -35.4% ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC. source
$GTHX +2.2% Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy. source
$ABOS -0.3% Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease. source
$SDGR +1.2% MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program. source
$JNCE +2.6% Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors. source
$SCYX +4.7% SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections. source
$ELDN +2.2% Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium. source
$CYTK +7.6% Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day. source
$IPSC -4.2% Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering. source
$FMTX -13.1% Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer. source
$TPTX -23.3% Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates. source
$CYDY -1.7% CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB). source
$MRUS +37.5% Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. source
Financial & Business Updates
$ALXO -6.7% ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio. source
$CALT -0.5% Calliditas announces acquisition of remaining Genkyotex minority shares. source
$AQST -3.0% Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement. source
$OSMT -37.6% Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million. source
Posted by FS
Comments